Effect of pemetinib/pemetinib on survival of patients with cholangiocarcinoma

Pemigatinib/Pemigatinib has had a positive impact on survival in patients with cholangiocarcinoma. As an FGFR inhibitor, pemetinib has shown significant efficacy against cholangiocarcinoma with FGFR gene mutations. Clinical trials have shown that patients treated with pemetinib have significantly longer survival compared with traditional treatments. This brings new hope to cholangiocarcinoma patients who face limited treatment options. However, the survival-prolonging effect may vary depending on individual differences, and further research and clinical data are still needed to confirm its long-term efficacy. Overall, pemetinib provides an effective treatment option for patients with cholangiocarcinoma and is expected to improve their survival prognosis.